Baudax Bio, Inc. (BXRX)
| Market Cap | 55.43M |
| Revenue (ttm) | 417,000 |
| Net Income (ttm) | -66.38M |
| Shares Out | 18.37M |
| EPS (ttm) | -3.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.30 |
| Previous Close | $1.33 |
| Change ($) | -0.03 |
| Change (%) | -2.26% |
| Day's Open | 1.33 |
| Day's Range | 1.28 - 1.37 |
| Day's Volume | 3,317,364 |
| 52-Week Range | 0.97 - 9.23 |
MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today ...
Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.
MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, th...
MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today ...
ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Bett...
Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript
BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have tran...
MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report th...
ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies
MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation...
MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the ...
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...
Baudax Bio: Discounted Despite Long-Term Prospects
MALVERN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awa...
MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies,...
Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript
Commenced Commercial Launch of ANJESO ® in the U.S.
Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement
Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Color...
MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered ...
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers On...
MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed o...
Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers
Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentatio...
Baudax Bio, Inc. (BXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MALVERN, Pa., April 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensat...
MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...
MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...
MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today ...
Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™ Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™
Tiny, Underfollowed Baudax Bio Way Too Cheap After Receiving FDA Drug Approval
Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & Drug Administration has BXRX stock taking off.
Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.
PDUFA Goal Date Set for February 20, 2020 PDUFA Goal Date Set for February 20, 2020
About BXRX
Baudax Bio, a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includ... [Read more...]
| Industry Biotechnology | |
| CEO Dr. Geraldine A. Henwood | Employees 24 |
| Stock Exchange NASDAQ | Ticker Symbol BXRX |
Analyst Forecasts
According to 3 analysts, the average rating for Baudax Bio stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 592.31% from the latest price.